Executive Summary
Burcon NutraScience Corporation, together with its subsidiary, develops plant proteins and ingredients for use in the food and beverage industries in Canada. More Details
Rewards
Risk Analysis
+ 1 more risk
Snowflake Analysis
High growth potential with adequate balance sheet.
Share Price & News
How has Burcon NutraScience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BU's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-9.3%
BU
3.9%
CA Chemicals
-1.0%
CA Market
1 Year Return
144.3%
BU
-13.4%
CA Chemicals
-4.3%
CA Market
Return vs Industry: BU exceeded the Canadian Chemicals industry which returned -15.4% over the past year.
Return vs Market: BU exceeded the Canadian Market which returned -4.2% over the past year.
Shareholder returns
| BU | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.3% | 3.9% | -1.0% |
| 30 Day | -20.1% | 4.5% | 1.3% |
| 90 Day | 15.6% | 23.3% | 1.9% |
| 1 Year | 144.3%144.3% | -9.1%-13.4% | -0.9%-4.3% |
| 3 Year | 207.1%207.1% | -30.6%-38.2% | 6.4%-4.0% |
| 5 Year | -9.7%-9.7% | -13.7%-28.8% | 33.3%12.8% |
Price Volatility Vs. Market
How volatile is Burcon NutraScience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Burcon NutraScience Corporation's (TSE:BU) Profit Outlook3 months ago | Simply Wall St
Is There An Opportunity With Burcon NutraScience Corporation's (TSE:BU) 30% Undervaluation?4 months ago | Simply Wall St
Loss-Making Burcon NutraScience Corporation (TSE:BU) Expected To BreakevenValuation
Is Burcon NutraScience undervalued compared to its fair value and its price relative to the market?
9.41x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BU (CA$2.15) is trading above our estimate of fair value (CA$0.93)
Significantly Below Fair Value: BU is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BU is unprofitable, so we can't compare its PE Ratio to the CA Chemicals industry average.
PE vs Market: BU is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BU is overvalued based on its PB Ratio (9.4x) compared to the CA Chemicals industry average (2.3x).
Next Steps
Future Growth
How is Burcon NutraScience forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
68.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: BU is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BU's is expected to become profitable in the next 3 years.
Revenue vs Market: BU's revenue (54.6% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: BU's revenue (54.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BU's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Burcon NutraScience performed over the past 5 years?
9.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BU is currently unprofitable.
Growing Profit Margin: BU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BU is unprofitable, but has reduced losses over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare BU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BU is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-17.5%).
Return on Equity
High ROE: BU has a negative Return on Equity (-21.05%), as it is currently unprofitable.
Next Steps
Financial Health
How is Burcon NutraScience's financial position?
Financial Position Analysis
Short Term Liabilities: BU's short term assets (CA$13.7M) exceed its short term liabilities (CA$1.3M).
Long Term Liabilities: BU's short term assets (CA$13.7M) exceed its long term liabilities (CA$6.3M).
Debt to Equity History and Analysis
Debt Level: BU's debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BU's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BU has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.8% each year.
Next Steps
Dividend
What is Burcon NutraScience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BU's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
11.1yrs
Average management tenure
CEO
Johann Tergesen (57 yo)
1.75yrs
Tenure
CA$369,034
Compensation
Mr. Johann Franz Tergesen, MBA, CPA, CA, serves as the President of Burcon NutraScience Corporation (formerly Burcon Capital Corp.) since September 2000 and serves as the Chief Executive Officer since Janu ...
CEO Compensation Analysis
Compensation vs Market: Johann's total compensation ($USD281.00K) is below average for companies of similar size in the Canadian market ($USD624.31K).
Compensation vs Earnings: Johann's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 1.75yrs | CA$369.03k | 3.25% CA$ 7.4m | |
| CFO & Treasurer | no data | CA$271.03k | 0.43% CA$ 979.0k | |
| Vice President of Technical Development | 11.08yrs | CA$218.00k | 0.16% CA$ 364.4k | |
| Senior VP of Legal & Corporate Secretary | 11.08yrs | CA$223.83k | 0.55% CA$ 1.3m | |
| Senior Vice President of Process | 18.92yrs | CA$287.88k | 0.72% CA$ 1.6m |
11.1yrs
Average Tenure
Experienced Management: BU's management team is seasoned and experienced (11.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director Emeritus | no data | CA$48.72k | no data | |
| Director | 21.92yrs | CA$60.22k | 0.80% CA$ 1.8m | |
| Independent Director | 9.08yrs | CA$79.29k | no data | |
| Independent Chairman | 1.75yrs | CA$92.36k | 0.19% CA$ 440.0k | |
| Director | 10.5yrs | CA$57.22k | no data | |
| Independent Director | 4.75yrs | CA$117.75k | 0.90% CA$ 2.1m | |
| Independent Director | 2.83yrs | CA$60.97k | no data | |
| Director | 1.25yrs | CA$53.47k | no data | |
| Independent Director | 0.25yr | no data | no data |
3.8yrs
Average Tenure
77yo
Average Age
Experienced Board: BU's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BU insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.
Top Shareholders
Company Information
Burcon NutraScience Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Burcon NutraScience Corporation
- Ticker: BU
- Exchange: TSX
- Founded: 1998
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CA$228.340m
- Shares outstanding: 106.20m
- Website: https://www.burcon.ca
Number of Employees
Location
- Burcon NutraScience Corporation
- 1946 West Broadway
- Vancouver
- British Columbia
- V6J 1Z2
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BU | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Feb 1999 |
| BNE | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Feb 1999 |
| BURO.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Feb 1999 |
Biography
Burcon NutraScience Corporation, together with its subsidiary, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company’s products include CLARISOY, a soy ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/22 00:04 |
| End of Day Share Price | 2020/10/21 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.